Status:
COMPLETED
PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Conditions:
Sarcoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
RATIONALE: Diagnostic procedures, such as PET scan and CT scan, may help doctors determine the extent of cancer and predict a patient's response to treatment and help plan the best treatment. PURPOSE...
Detailed Description
OBJECTIVES: * Determine whether an FDA-approved device that combines fludeoxyglucose \^18F positron-emission tomography (FDG-PET) and CT scanning (FDG-PET/CT) can accurately locate and determine the ...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed bone or soft tissue sarcoma
- Scheduled to undergo treatment (i.e., chemotherapy and/or radiotherapy) for sarcoma
- Negative pregnancy test
- Fertile patients must use effective contraception
- Not claustrophobic
- Able to lie supine for 1 hour
- Patients with diabetes mellitus allowed provided serum glucose levels ≤ 200 mg/dL
Exclusion
- pregnant
- other malignancies within the past 5 years (except completely resected cervical or nonmelanoma skin cancer) unless the malignancy was curatively treated and is at low risk for recurrence
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00335751
Start Date
January 1 2006
End Date
October 1 2011
Last Update
July 31 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States, 90095-1781